Nikki Haley responds to Liz Cheney’s criticism of her Trump support
Nikki Haley, former governor of South Carolina and 2024 Republican presidential candidate, speaks during a campaign event in Washington, Mar. 1, 2024. (Graeme Sloan/Bloomberg via Getty Images)
(WASHINGTON) — Former Republican presidential candidate Nikki Haley pushed back against criticism from former Republican Rep. Liz Cheney on Haley’s support for former President Donald Trump despite previous comments saying she found him unfit for office.
In an exclusive This Week interview on Sunday, ABC News co-anchor Jonathan Karl asked Cheney about Haley saying she’s on “standby” to campaign for Trump after the former South Carolina governor openly opposed him in the Republican primaries.
Cheney, who last week endorsed Vice President Kamala Harris, told Karl, “I can’t understand [Haley’s] position on this in any kind of a principled way. I think that, you know, the things that she said, that she made clear when she was running in the primary, those things are true.”
During the Republican presidential primary, Haley said Trump lacked focus and that “chaos follows him.” Months later, Haley said she would vote for Trump despite her disappointment with him.
Reacting to Cheney’s remarks, Haley told Fox and Friends Monday morning, “I respect her decision, but she can’t say my decision is not principled. It actually is.”
“We can either vote based on style or we can vote on substance. I’m voting based on substance,” she continued. “I’m looking at the fact we can’t live the next four years like we did the last four years. This is no contest.”
Seeking to contrast Trump with Harris on the economy, border and energy, Haley added, “We should be very clear, if you don’t like him, say you don’t like him, but you can’t say that his policies are worse than Kamala Harris’.”
Haley also directly criticized Trump and running mate Sen. JD Vance when asked about the “gender gap” with women supporting Harris more than Trump.
“I think it’s because Donald Trump and JD Vance need to change the way they speak about women. You don’t need to call Kamala dumb. She didn’t get this far, you know, just by accident — she’s here. That’s what it is. She’s a prosecutor,” Haley said. “You don’t need to go and talk about intelligence, or looks or anything else. Just focus on the policies. When you call even a Democrat woman dumb, Republican women get their backs up too.”
Last month, Trump said he’s “entitled” to the personal attacks aimed at Harris — because he doesn’t respect her and doesn’t “have a lot of respect for her intelligence.”
Haley reiterated that Trump should ditch those attacks to focus on substance.
“The bottom line is, we win on policy. Stick to the policies, leave all the other stuff. That’s how he can win,” Haley said.
(STATESBORO, Ga.) — Len Fatica is a member of a political species that’s practically extinct in deep red Statesboro, Georgia — a rural Democrat.
ABC News traveled to the biggest city in Georgia’s southeastern Bulloch County, with a population of around 34,000. It boasts four different Main Streets (one for each point of the compass) and a persistent gnat problem.
“People are, for the most part, very friendly,” Fatica, the Georgia Democratic Party’s rural council chair, told ABC News. “They will sit down and have a conversation with you even if they disagree with you.”
Plenty of people disagree with Fatica, who’s running for county commission and leading an initiative to attract rural voters to the state Democratic Party. They meet each week at a local coffee shop to talk strategy, and he acknowledged how difficult it is for Democrats to make inroads in rural areas.
“If you look at Bulloch County down here, we’re probably close to 70% that is Republican,” he said. “This is a deep Republican area.”
Fatica accepted the persistent criticism that Democrats left rural voters behind long ago in favor of urban populations, but he believes locals might be gradually drawn back — a possibility suggested when Joe Biden narrowly won the swing state in the 2020 presidential election.
“At one time, it was a Democratic county,” he said. “Talking to Republicans, they feel within 10 years, with the manufacturing jobs that are being moved in, this could become a Democratic county again.”
Fatica highlighted the importance of Democrats taking on Trump’s rhetoric, even when talking to deep red voters.
“We’ve got to punch back, and we’ve got to punch back on the falsehoods that are told,” he said.
Vice President Kamala Harris’ choice of running mate might also move the needle, according to Fatica. Minnesota Gov. Tim Walz, who formally accepted the nomination at the Democratic National Convention on Wednesday, regularly highlights his rural roots in speeches and rallies.
“Growing up I spent the summers working on the family farm,” Walz said on Aug. 6. “My mom and dad taught us — show generosity toward your neighbors and work for the common good.”
Lifelong Democrats Robin Hutcheson and her daughter Aliya Johnson highlighted how unusual they are, living in Republican Rep. Marjorie Taylor Greene’s northwest Georgia congressional district.
“You see a lot of trucks with Trump flags and a lot of Trump flags in the yard, and we are like little blue dots in a big red sea,” Hutcheson said.
They agreed that Walz could appeal to rural Americans.
“I feel like Tim is genuinely a person who has high morals, who is a good, upstanding person,” Johnson said. “That kind of represents the older style of respectability that I think older voters got used to and that newer voters still want to lean on and believe is the right thing, and a good thing.”
The mother and daughter agreed that Democrats haven’t been this excited since Obama’s bids for the White House.
“This is the first time that we really feel like change is possible,” Johnson said.
Political strategist Fred Hicks noted his belief that Georgia has become competitive because many of the culture wars that defined America for generations have subsided — there are multiple issues rather than a single issue driving people to vote.
“The economic issue is really what’s, I think, pushing people because you have not had the economic growth outside of these urban nodes,” Hicks said of the rural areas.
Peter Fuller is the chair of the northeastern Jackson County’s Democratic Party and knows flipping any rural part of Georgia is a tall order. Trump won 78% of the Jackson County vote in 2020.
“These are counties that have been like this for a while. They are long-term projects,” he said. “Most of these communities are agriculture based. We have issues of either not having population growth, or loss in some cases. Health care is a big one.”
Fuller noted that translating some national policies into something relatable for Jackson County voters can be challenging.
“It’s a lot easier to do with somebody like Tim Walz,” he said.
What remains to be seen is whether the hope and excitement around the Harris-Walz ticket can translate into votes and victory for the Democratic Party in rural America.
(WASHINGTON) — Former President Donald Trump said on Thursday he will not take part in any more debates ahead of the 2024 election.
In a post on his social media platform, Trump argued that Vice President Kamala Harris could’ve accepted an offer to debate on Fox News on Sept. 4, or could’ve negotiated a second debate before the ABC News debate.
“She was a no-show at the Fox Debate, and refused to do NBC & CBS. KAMALA SHOULD FOCUS ON WHAT SHE SHOULD HAVE DONE DURING THE LAST ALMOST FOUR YEAR PERIOD. THERE WILL BE NO THIRD DEBATE!” Trump posted on his social media platform. ” Trump wrote.
Harris had challenged Trump to another showdown immediately after Tuesday’s matchup in Philadelphia, Pennsylvania.
Harris took the stage at a rally in Charlotte, North Carolina, just after Trump’s announcement. Although she did not cite Trump’s social media post, Harris said he and she “owe it to the voters to have another debate.”
“Two nights ago, Donald Trump and I had our first debate, and I believe we owe it to the voters to have another debate,” Harris said. “Because this election and what is at stake could not be more important. On Tuesday night, I talked about issues that I know matter to families across America, like bringing down the cost of living, investing in America’s small businesses, protecting reproductive freedom and keeping our nation safe and secure.”
“But that’s not what we heard from Donald Trump,” she continued. “Instead, it was the same old show, that same tired playbook that we have heard for years, with no plans for how he would address the needs of the American people because, you know, it’s all about him, it’s not about you. Well, folks, I said it then, I say it now, it’s time to turn the page.”
ABC News’ Will McDuffie, Gabrielle Abdul-Hakim and Fritz Farrow contributed to this report.
(WASHINGTON) — Senators grilled Novo Nordisk CEO Lars Jørgensen Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs, requesting explanations for why the U.S. faces a higher list price than other countries.
Since first entering the market nearly six years ago, the drugs have risen in popularity for diabetic patients and others looking to combat obesity. But doctors and patients have faced challenges in access and affordability.
Sitting in front of a chart showing the lower prices for Wegovy and Ozempic in other countries, Sen. Bernie Sanders, I-Vt., the chair of the Senate Health Committee, pressed Jørgensen on why it’s fair to charge more in the U.S.
“All we are saying, Mr. Jørgensen, is treat the American people the same way that you treat people all over the world. Stop ripping us off,” Sanders said to Jørgensen.
Sanders asked Jørgensen why the U.S. faced higher prices. Novo Nordisk charges $969 per month for Ozempic in the U.S., compared to $155 per month in Canada and $59 in Germany. For Wegovy, the price is $1,349 per month in the U.S., but $265 in Canada and $137 in Germany.
“Bottom line is, you are charging the American people substantially more for the same exact drug than you are charging people in other countries. And my question is, why?” Sanders asked.
The CEO said the company was spending $30 billion to increase its production and access to the drugs. He also highlighted a 40% decrease in cost since Ozempic came on the market and a sliding scale of costs for people across the U.S., including programs for low-income Americans to access the medicine for cheaper.
But ultimately, Jørgensen cast the blame on the complexities of the U.S. health care system.
“Senator, we are very committed to make sure that Americans have access at an affordable price point for our medicines. There’s nothing we would rather see happen. We have just announced $30 billion in investments to increase capacity to serve these patients. There is a market we have to operate in, and we negotiate hard to make sure that Americans have access,” he said.
“With that said, it is clear that patients too often struggle to navigate the complex US health care system. It’s also clear that no single company alone can solve such vast and complicated policy changes,” Jørgensen added.
Novo Nordisk isn’t responsible for deciding what price patients pay their insurance companies, he said, and he argued that pharmacy benefit managers, or companies that help oversee prescription drug benefits and control costs, get in the way of companies passing discounts on directly to patients.
But Jørgensen didn’t provide a direct answer to why the U.S. faces a higher list price than other countries, instead pointing to “a very complex market and very complex health care system that creates a lot of misunderstandings.”
“Everyone blames everyone else,” Sanders said, from pharma companies to PBMs to insurance companies.
Sanders connected the high prices of Wegovy and Ozempic to something he’s made the center point of his career, including his 2016 and 2020 campaigns: corporate greed.
“Are they acting illegally by charging us some such high prices? Are they violating the law? No, they’re not. What they’re doing is perfectly lawful. They are simply taking advantage of the fact that, until very recently, the United States has been the only major country on earth not to negotiate the cost of prescription drugs,” Sanders said.
“In other words, Novo Nordisk and other drug companies, not just Novo Nordisk, can charge us as much as the market can bear, and that is precisely what they are doing,” he added.
Jørgensen and a handful of Republican senators, including ranking member Sen. Bill Cassidy, pointed out that wholesale prices don’t offer a completely apples-to-apples picture because, in the U.S., insurance and rebates typically reduce the price patients pay by a significant amount.
“There is a tension, a tension between the need to incentivize innovation and the ability to afford that innovation. We are here struggling with that balance,” Cassidy, who is a physician, said. “If anyone thinks going after big pharma is the silver bullet that if you do that, boom, health care costs or drug costs go down, they don’t understand what happens with pricing a drug.”
Sanders dismissed that argument, however, saying it’s still unfair for the initial list prices to be higher in the U.S. It trickles down to the U.S. patient, Sanders said, leaving Americans with higher prices even with rebates or insurance. Of course, uninsured Americans — around 8% of the country — also pay the full list price.
“Even factoring in all of the rebates that [pharmacy benefit managers] receive, the net price for Ozempic is still nearly $600 — over nine times as much as it costs in Germany. And the estimated net price of Wegovy is over $800 — nearly four and a half times as much as it costs in Denmark,” Sanders said.
When it comes to insurance coverage, drug prices become a “pass through to the insurance companies” resulting in higher plan prices, Sanders argued.
“What must also be understood is that not everybody can take advantage of the net price of these drugs. If you are uninsured, you pay the full list price. If you have a large deductible, you pay the full list price. If you have co-insurance, the percentage of the price you pay at the pharmacy counter is based on the list price,” Sanders said.
Novo Nordisk continued to place the blame on health insurance middlemen for the high drug prices in a statement released after the hearing.
“Our hope is that the conversation with the HELP Committee will result in real and tangible solutions that benefit patients and allow millions of people living with these serious and chronic diseases to be the direct beneficiaries of real change,” the company said. “While no single company can fix the American healthcare system alone, we look forward to continuing to work with policymakers and other stakeholders toward meaningful solutions for the people who rely on our medicines.”
ABC News’ Eric Strauss contributed to this report.
